Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: Mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method

Table 2 Infection syndrome, treatment and outcome of nosocomial bacteremia in patients infected with high MIC MRSA or low MIC MRSA

Syndrome & treatment	Vancomycin MIC < 2 N = 97 Number of patients (%)	Vancomycin MIC = 2 N = 26 Number of patients (%)	p-value ^a
Syndrome
Primary bacteremia	18 (18.6)	5 (19.2)	0.938
Pneumonia	32 (33.0)	9 (34.6)	0.876
Catheter related infection	40 (41.2)	12 (46.2)	0.652
Prosthesis	6(6.2)	0 (0)	0.341
Infective endocarditis	6 (6.2)	0 (0)	0.341
Treatment
Empirical glycopeptide use within 48 hours	71 (73.2)	19 (73.1)	1.000
Vancomycin trough level (mg/L)	14.9 ± 7.6 (n = 47)	13.5 ± 4.9 (n = 12)	0.176
Vancomycin trough level > 10 mg/L in first week	34 (72.3)	9 (75.0)	1.000
With a DNR order^b	26 (26.8)	11 (42.3)	0.151
Outcome
2 week death	14 (14.4)	8 (30.8)	0.081
30 days death	27 (27.8)	13 (50.0)	0.057

ISSN: 1471-2334